The effect of microbiome-modulating therapeutics on glucose homeostasis in metabolic syndrome: A systematic review, meta-analysis, and meta-regression of clinical trials
<h3>Background</h3><p dir="ltr"><u>Metabolic syndrome</u> (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and <u>carbohydrate metabolism</u>. Microbiome-modulating<u> probiotics, prebio...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , , , , |
| منشور في: |
2024
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| الملخص: | <h3>Background</h3><p dir="ltr"><u>Metabolic syndrome</u> (MetS) is a chronic disorder featuring overweight/obesity, high blood pressure, and dysfunction of lipid and <u>carbohydrate metabolism</u>. Microbiome-modulating<u> probiotics, prebiotics, synbiotics</u> and <u>fecal microbiota</u> transplant (FMT) are promising adjunct therapies for improving parameters of <u>glucose homeostasis</u> and insulinemia. </p><h3>Methods</h3><p dir="ltr">We conducted a comprehensive <u>systematic review</u>, meta-analyses, and meta-regressions to investigate the effect of the abovementioned microbiome therapies on various biomarkers after screening <u>clinical trials</u> published through April 2023. We pooled data using random effects meta-analyses, reporting them as mean differences (MDs) with 95 % confidence intervals (CIs), and conducting univariate linear model meta-regressions. </p><h3>Results</h3><p dir="ltr">Data from 21 trial comparisons across 19 studies (n = 911) revealed that, compared to placebo/control, microbiome-modulating therapies were associated with statistically significant changes in fasting <u>plasma glucose</u> (MD: 4.03 mg/dL [95%CI: 6.93; −1.13]; p<sub>effect</sub> = 0.006, I<sup>2</sup> = 89.8 %), and fasting insulin (MD: 2.56 μU/mL [95%CI: 4.28; −0.84]; p<sub>effect</sub> = 0.004, I<sup>2</sup> = 87.9 %), but not insulin resistance or sensitivity indices and <u>HbA1c</u>. Age, baseline <u>BMI</u>, baseline biomarker value, pro/synbiotic dosage, trial duration, <u>nutraceutical</u> type, and WHO region were factors affecting the efficacy of these interventions at producing changes in biomarkers, signaling the potential role of personalized precision medicine adjunct therapy for deranged <u>glucose homeostasis</u> in patients with MetS. Nevertheless, presence of heterogeneity calls for further investigation before their clinical application. </p><h3>Conclusions</h3><p dir="ltr">Probiotics, <u>prebiotics, synbiotics </u>and FMT supplementation improved fasting glucose and insulin in patients with MetS. Further large-scale and high-quality trials are required before potential clinical applications.</p><h2>Other Information</h2><p dir="ltr">Published in: Diabetes & Metabolic Syndrome: Clinical Research & Reviews<br>License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.dsx.2024.103118" target="_blank">https://dx.doi.org/10.1016/j.dsx.2024.103118</a></p> |
|---|